Akari Therapeutics (AKTX)
(Delayed Data from NSDQ)
$1.02 USD
-0.03 (-2.86%)
Updated Aug 12, 2025 03:32 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKTX 1.02 -0.03(-2.86%)
Will AKTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AKTX
Morning Movers: Under Armour sinks following second quarter earnings
Akari Therapeutics sees cash runway into 2028
Akari Therapeutics reports Q2 EPS (86c) vs. (81c) last year
AKTX: Akari Therapeutics Discusses Progress in Cancer Research
Akari Therapeutics releases 'What This Means' segment for investors